Record overview
Status and phase
Status: UNKNOWN
Phase: PHASE2
Sponsor: Peking Union Medical College Hospital
Condition: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm
NCT05113355
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Unknown Status Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.